These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7820183)

  • 1. Growth of tumor derived activated T-cells for the treatment of cancer.
    Lewko WM; Good RW; Bowman D; Smith TL; Oldham RK
    Cancer Biother; 1994; 9(3):211-24. PubMed ID: 7820183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth of tumor-derived activated T cells for the treatment of advanced cancer.
    Lewko WM; Hall PB; Oldham RK
    Cancer Biother Radiopharm; 2000 Aug; 15(4):357-66. PubMed ID: 11041020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-15 and the growth of tumor derived activated T-cells.
    Lewko WM; Smith TL; Bowman DJ; Good RW; Oldham RK
    Cancer Biother; 1995; 10(1):13-20. PubMed ID: 7780482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.
    Oldham RK; Dillman RO; Yannelli JR; Barth NM; Maleckar JR; Sferruzza A; Cohen RJ; Minor DR; Spitler L; Birch R
    Mol Biother; 1991 Jun; 3(2):68-73. PubMed ID: 1910622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 11. Expansion of activated lymphocytes obtained from renal cell carcinoma in an automated hollow fiber bioreactor.
    Hillman GG; Wolf ML; Montecillo E; Younes E; Ali E; Pontes JE; Haas GP
    Cell Transplant; 1994; 3(4):263-71. PubMed ID: 7921631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy.
    Yannelli JR; Crumpacker DB; Good RW; Friddell CD; Poston R; Horton S; Maleckar JR; Oldham RK
    J Immunol Methods; 1990 Jun; 130(1):91-100. PubMed ID: 1972724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells take aim at cancer.
    Pardoll D
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
    Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
    Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
    J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.